Green tea compound may improve cancer drugs

Conclusion This study developed a new way of packaging and carrying protein drugs by combining them with a green tea extract called Epigallocatechin-3-O-gallate (EGCG), which itself may have anti-cancer properties. They formed a complex between derivatives of EGCG and the protein cancer drug Herceptin. Tests in the laboratory and in mice indicated it might have better anti-cancer properties than non-complexed free Herceptin. This is encouraging research and may lead to improvements in delivery mechanisms for protein drugs further down the line. But this research remains at a very early stage of development. The results from the laboratory and mice studies need to be confirmed by other research groups before the team can consider testing potential treatments in humans. Only then will they be able to assess whether such a drug delivery system could benefit people. These further studies will have to pay special attention to potential side effects of the drugs. Green tea extracts are often the subject of news headlines, often in the very early stages of drug development. Other claims made about green tea include how it can help prevent prostate cancer, reduce stroke risk, boost the ability of the brain, and help ward off Alzheimer's disease. Some people have even gone as far as claiming the beverage is a “"superfood". Many of these claims are not backed by robust evidence, however. Overall, this new nanotechnology might prove useful in many years' t...
Source: NHS News Feed - Category: Consumer Health News Tags: Cancer Medication Source Type: news

Related Links:

Is it time to bring circulating tumor cell assays to the forefront of breast cancer surveillance?Journal of the National Cancer Institute
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Conclusions: The surgical procedure for axillary lymph node dissection should be considered to avoid prolonged fluid discharge, and the lymph vessels should be ligated in axillary lymph node dissection. An ultrasonic dissector was not effective in reducing the total fluid discharge volume. An optimal axillary lymph node dissection technique should be developed. For the patients without drainage, careful postoperative treatment should be given to avoid infectious seroma formation, even for patients who underwent total mastectomy with sentinel lymph node retrieval. PMID: 31114633 [PubMed]
Source: Patient Safety in Surgery - Category: Surgery Authors: Tags: Patient Saf Surg Source Type: research
Publication date: Available online 22 May 2019Source: The LancetAuthor(s): Shelagh B Coutts, Bijoy K Menon
Source: The Lancet - Category: General Medicine Source Type: research
This study is registered with the ISRCTN registry, number ISRCTN69371850.FindingsBetween April 14, 2014, and April 30, 2018, 770 participants were enrolled and randomly assigned to either robot-assisted training (n=257), EULT (n=259), or usual care (n=254). The primary outcome of ARAT success was achieved by 103 (44%) of 232 patients in the robot-assisted training group, 118 (50%) of 234 in the EULT group, and 85 (42%) of 203 in the usual care group. Compared with usual care, robot-assisted training (adjusted odds ratio [aOR] 1·17 [98·3% CI 0·70–1·96]) and EULT (aOR 1·51 [0·9...
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: Available online 22 May 2019Source: The LancetAuthor(s): Julie Bernhardt, Jan Mehrholz
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: Available online 22 May 2019Source: The LancetAuthor(s): Colin Baigent, Daniel Lasserson, Frank Sullivan, Johanna Carrie, Javier Rojas, Shannon Amoils, John Bamford, Jane Armitage, Gabriel Rinkel, Gordon Lowe, Jonathan Emberson, Karen Innes, Lynn Dinsmore, Jonathan Drever, Carol Williams, David Perry, Connor McGill, David Buchanan, Allan Walker, Aidan HutchisonSummaryBackgroundAntiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial hae...
Source: The Lancet - Category: General Medicine Source Type: research
This study is registered with PROSPERO, number CRD42019128036.FindingsWe identified three trials that met eligibility criteria: EXTEND, ECASS4-EXTEND, and EPITHET. Of the 414 patients included in the three trials, 213 (51%) were assigned to receive alteplase and 201 (49%) were assigned to receive placebo. Overall, 211 patients in the alteplase group and 199 patients in the placebo group had mRS assessment data at 3 months and thus were included in the analysis of the primary outcome. 76 (36%) of 211 patients in the alteplase group and 58 (29%) of 199 patients in the placebo group had achieved excellent functional outcome a...
Source: The Lancet - Category: General Medicine Source Type: research
Conclusion: Prognosis in advanced stage CCA is still very poor. However, multimodal treatment in palliative patients significantly prolong survival.Digestion
Source: Digestion - Category: Gastroenterology Source Type: research
Background The role of perioperative systemic therapy (PST) in the management of localized pancreatic neuroendocrine neoplasms (PanNEN) is unclear. Objectives We aimed to evaluate the benefit of PST compared to surgical alone (SA) in patients with localized PanNEN. Method We selected patients with stage I-III PanNEN who underwent curative-intent surgical resection in National Cancer Database from 2006 to 2014. Patients who had both PST and surgical resection were matched with patients who received SA by propensity score at 1-to-1 ratio with nearest neighbor method. Results 4,892 patients were included in this study ...
Source: Neuroendocrinology - Category: Endocrinology Source Type: research
Torrent Pharmaceuticals Limited is voluntarily recalling 14 lots of Valsartan/Amlodipine/HCTZ tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
More News: Alzheimer's | Biology | Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Gastric (Stomach) Cancer | Green Tea | Harvard | Health | Herceptin | Laboratory Medicine | Middle East Health | Nanotechnology | Neurology | Prostate Cancer | Science | Stroke | Study | Tea | Toxicology